Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Subscribe To Our Newsletter & Stay Updated
